APMD (Apnimed) Total Stockholders Equity: $257.59 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APMD Apnimed Inc APMD
8 GF Score
Price $25.00
View Full Analysis

What is Apnimed Total Stockholders Equity?

Apnimed APMD +13.64% 8 Total Stockholders Equity is $257.59 Mil as of Mar. 2026. GuruFocus rates APMD with a GF Score™ of 8/100.

Apnimed's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $257.59 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Apnimed's Book Value per Share for the quarter that ended in Mar. 2026 was $6.78. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Apnimed's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.18.

Apnimed  (NAS:APMD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Apnimed's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(257.59-0)/38.000
=6.78

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Apnimed's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.257 + 46.655) / 257.59
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apnimed Total Stockholders Equity Related Terms

Apnimed Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Apnimed's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apnimed Total Stockholders Equity Chart

Apnimed Annual Data
Trend Dec24 Dec25
Total Stockholders Equity
-248.62 -372.78

Apnimed Quarterly Data
Dec24 Mar25 Dec25 Mar26
Total Stockholders Equity -248.62 0.00 -372.78 257.59
APMD
8GF Score
Apnimed Inc APMD
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $257.59 Mil mean?
Apnimed (APMD) has a Total Stockholders Equity of $257.59 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Apnimed and its competitors.
Is Apnimed's Total Stockholders Equity too high?
Apnimed's current Total Stockholders Equity is $257.59 Mil. Overall, Apnimed has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Apnimed's Total Stockholders Equity compare to ?
Apnimed's Total Stockholders Equity of $257.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Apnimed and its competitors. Apnimed's current Total Stockholders Equity is $257.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apnimed stock overvalued right now?
Apnimed (APMD) has a current Total Stockholders Equity of $257.59 Mil. The current Total Stockholders Equity is $257.59 Mil. Apnimed's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Apnimed (APMD), the current Total Stockholders Equity is $257.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apnimed Business Description

Comparable Companies
Address 39 John F. Kennedy Street, 4th Floor, Cambridge, MA, USA, 02138
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
8GF Score

Get the complete analysis for APMD

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price